Auro Laboratories Ltd Dividend

Auro Laboratories Ltd Dividend - Payout, Yield & Future Updates

Image

Auro Laboratories Ltd

NSE: AUROLABS

Dividend Payout (-)

-

Ex-Dividend Date: NA

Auro Laboratories Ltd Dividend - History

swot
swot

Monitoring Auro Laboratories Ltd share price can help you stay informed about potential market shifts and opportunities.

Dividend Payout Over Time

No data available

Overview of Dividend

  • <h2><strong>Types of Dividend</strong></h2><br> <h3>Special Dividend</h3> <p>A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.</p> <br> <h3>Preferred Dividend</h3> <p>A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.</p> <br> <h3>Interim Dividend</h3> <p>Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.</p> <br> <h3>Final Dividend</h3> <p>A final dividend is issued after the year's accounts have been compiled.
  • Aside from this, the following list highlights the most prevalent sorts of dividends:</p> <br>.

Types of Dividend


Special Dividend

A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.


Preferred Dividend

A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.


Interim Dividend

Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.


Final Dividend

A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:


Dividend Yield Comparison With Top Peers

* All values are in %

Image

Auro Laboratories Ltd

NSE: AUROLABS

Share Price

₹ -

Last updated on: Jan 01, 2026

Company Fundamentals for Auro Laboratories Ltd

Dividend Payout Over Time

No data available

Net Profit Vs Dividend Per Share

SWOT Analysis Of Auro Laboratories Ltd

Strength

1

che

Weakness

1

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Auro Laboratories Ltd

Historical Market Cap of Auro Laboratories Ltd

Market Cap

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Auro Laboratories Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Auro Laboratories Ltd News Hub

Auro Laboratories standalone net profit rises 5.63% in the June 2024 quarter

Net profit of Auro Laboratories rose 5.63% to Rs 0.75 crore in the quarter ended June 2024 as agains

Read more

10 Aug 24

Auro Laboratories to announce Quarterly Result

Auro Laboratories will hold a meeting of the Board of Directors of the Company on 9 August 2024 Powe

Read more

01 Aug 24

Auro Laboratories to hold board meeting

Auro Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2024 P

Read more

06 Nov 24

Auro Laboratories standalone net profit declines 81.73% in the September 2024 quarter

Net profit of Auro Laboratories declined 81.73% to Rs 0.36 crore in the quarter ended September 2024

Read more

12 Nov 24

About Auro Laboratories Ltd

  • Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
  • Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
  • The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
  • The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
  • Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions